50+ Topics on Nucleic Acid Therapeutics: Driving Innovation, Technological Breakthroughs, and CMC Research

The 5th Nucleic Acid Drug Frontier Innovation SummitWill beJuly 2-3, 2026InShanghaiGrand Opening. The summit brings together50+Industry Leaders and800+Fellow professionals in the industry, focusUnderlying Innovation, Clinical Breakthroughs, and Process Research in Nucleic Acid DrugsAnd other related topics, deeply explore the R&D challenges, comprehensively interpret market trends and future opportunities, promote continuous innovation breakthroughs in nucleic acid and related drugs, and contribute to the high-quality development of the industry!

Hosted by: Yao Xiangzhi

Meeting Time: July 2-3, 2026

Meeting Location: Shanghai

• Topic of the speech to be determined

  Wang HaishengSicaGeneFounder andCEO

• AOC Drugs: The Golden Track for Nucleic Acid Therapies to Move from "Internal Competition" to "Breakthrough"

  Zhao ChengjiangYoujia (Hangzhou) Biomedical Technology Co., Ltd.President of the Nucleic Acid Drug Research Institute

• Advances in Circular RNA Drug Development

  Tang Chenxiang, CEO of CirCode

• How Anlong Responds to the Red Ocean of Small Nucleic Acids in China

  Chunlin Zhao, Founder of Anlong Biotech / Founding Partner of Anlong Fund

• Topic of the speech to be determined

  Yang XianbinBeforeSaint Noir Group Greater China RegionCSO

• Current Status and Development Trends of the Nucleic Acid Drugs Market

  Li Qian, Executive Director of Frost & Sullivan

• Innovation Modification and Precise Delivery Empower Small Nucleic Acid Drugs for Clinical Translation

  Haitao Li Co-founder / Chief Technology Officer of Xuanjing Bio

• Dual-target and Extrahepatic Delivery Technology of Small Nucleic Acids

  Liu Guocheng, CSO of Small Nucleic Acids at Xuanzhu Biotechnology Co., Ltd.

• Novel Silicon Nanoparticle Transdermal Delivery Technology and siRNA Drug Development

  Tang Shenggao, Founder of PrimeBiotech (Suzhou) Co., Ltd.

• Topic of the speech to be determined

  Wang HaotianFounder & CEO of Higend Sciences

• Development of Small Nucleic Acid Delivery Technology and Products for the Nervous System
  

  Guo Wei, Professor at China Pharmaceutical University

• Topic of the speech to be determined

  Zhang WeiguoRenjing Bio (Suzhou)Vice President of R&D

• Delivery System for Nucleic Acid Drugs

  Li Jianguang, CSO of Zhejiang HaiChang
  
• Current Status and Trends in the Research and Development of Small Nucleic Acid Drugs for Obesity
  Wang Yanhui, Head of siRNA Drug Discovery at Innovent Biologics
  
• Delivery Systems Empower the Development of Next-Generation Antibody-Drug ConjugatesHarmony ResponseUse
  Fang Zihui, CEO of Yino Biotech
  
• Small Activating RNA Opens Up New Blue Ocean for Difficult Drug Targets
  Xie WenkaiChief Strategy Officer of RiboNova

• Topic of the speech to be determined

  Dr. Huang Jin YuCo-founder and Senior Vice President of Chemistry at Daring Biopharmaceuticals Co., Ltd.

• Nonclinical Research and Evaluation of Oligonucleotide Drugs

  Hu Xiaomin, Former Director Pharmacist/Senior Reviewer of CDE, National Medical Products Administration
  

• The Next-Generation Technology Layout of Small Nucleic Acid Drugs

  Huang Yi General Manager of the Innovative Drug Division, Chengdu Guowei Biopharmaceutical Co., Ltd.
  

• Progress in Small Nucleic Acid Therapies for HBV (Proposed)

  Guo Na, Head of the Medical Department and Transformation Center of Henan Real Biotechnology Co., Ltd.

• Roundtable Guests

  Cai KunShanghai Zhaowei Technology Development Co., Ltd.Assistant to the President/CTO

  Hu RongkuanStellar PharmaCEO

  More guest topics are being confirmed...

• CMC Strategy for the Entire Life Cycle
  

  Li Jiuyuan, General Manager of AAND Biotechnology (Tianjin) Co., Ltd.

• Topic of the speech to be determined

• LI QingDesano Group Tianjin PharmaCEO

• A Brief Analysis of Quality Control and Impurity Research in Oligonucleotide Drugs

  Kong SudongSuZhoubei Xin Biomedical Technology Co., Ltd.CEO

• Oligonucleotide DrugsCMC Key Process Challenges and Strategies
  

  Zhou XiaoViya Zhen Biotechnology (Shanghai) Co., Ltd.CMC Director

• Oligonucleotide DrugsCMC Process Challenges and Technical Breakthroughs

  Zhang Yu Senior Director of R&D at Hangzhou Nuotai Nuhe Biomedical Technology Co., Ltd.

• Research and Quality Control of Oligonucleotides
  More guest topics to be confirmed...

  
  

• Topic of the speech to be determined

  Hui AiminFounder/Chairman of Huizhengqi Medicine/CEO      

• Topic of the speech to be determined

  Wang Peng President of the Glycobiology Branch of the Chinese Biophysical Society / Director of the China Heparin Research Center, Pingshan Biomedical Research Institute, Southern University of Science and Technology

• Development and Performance Study of Novel Xenonucleic Acids (XNA)

  Mei Hui, Associate Researcher of Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences

• Ultra-High-Throughput Functional Nucleic Acid Screening Technology and Applications

  Zhao Feng Luo, Professor-level Senior Engineer at the Hangzhou Institute of Medicine, Chinese Academy of Sciences / Co-founder & Deputy Director of the Aptamer Screening Center

• Can microRNA (miRNA) be druggable?

  Li Hao, Chairman of Livet Biopharmaceutical Co., Ltd.

• NovelmRNA Therapeutic Vaccine CG-1999 Achieved Complete Clearance of HBV Infection in a Mouse Model of Hepatitis B

  Chen XiaowuShanghai Kejun PharmaceuticalVice President of Chemistry

• PreventivemRNA Vaccines: Opportunities and Challenges
  Qiu Yuanzheng, General Manager of the Vaccine Clinical Center at CSPC Group

• AI Develops Global LNP-mRNA Innovative Products

  Xia Fang3D MedicinesVice President and Board Secretary

• Research on Non-Viral Vector-Mediated In Vivo CAR-T

  Xiong Changyun, CEO of Ningbo Junjian Biotechnology Co., Ltd.

• Topic of the speech to be determined

  Tian Weiwei, Vice General Manager of Sirnaomics

  More guest topics to be confirmed...